CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer.
Liu S, Meng Y, Liu L, Lv Y, Yu W, Liu T, Wang L, Mu D, Zhou Q, Liu M, Ren Y, Zhang D, Li B, Sun Q, Ren X.
Liu S, et al. Among authors: mu d.
Cell Death Dis. 2022 May 6;13(5):441. doi: 10.1038/s41419-022-04882-x.
Cell Death Dis. 2022.
PMID: 35523765
Free PMC article.
Clinical Trial.